Mohammad Alzrigat

472 total citations
15 papers, 317 citations indexed

About

Mohammad Alzrigat is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Mohammad Alzrigat has authored 15 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Mohammad Alzrigat's work include Histone Deacetylase Inhibitors Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Mohammad Alzrigat is often cited by papers focused on Histone Deacetylase Inhibitors Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Mohammad Alzrigat collaborates with scholars based in Sweden, United States and Canada. Mohammad Alzrigat's co-authors include Helena Jernberg‐Wiklund, Anqi Ma, Fredrik Öberg, Jian Jin, Antonia Kalushkova, Kenneth Nilsson, Prasoon Agarwal, Anders Österborg, Jonathan D. Licht and Thomas Stamminger and has published in prestigious journals such as Nature Communications, The Journal of Cell Biology and International Journal of Molecular Sciences.

In The Last Decade

Mohammad Alzrigat

14 papers receiving 315 citations

Peers

Countries citing papers authored by Mohammad Alzrigat

Since Specialization

Citations

This map shows the geographic impact of Mohammad Alzrigat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Alzrigat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Alzrigat more than expected).

Fields of papers citing papers by Mohammad Alzrigat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Alzrigat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Alzrigat. The network helps show where Mohammad Alzrigat may publish in the future.

Co-authorship network of co-authors of Mohammad Alzrigat

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Alzrigat. A scholar is included among the top collaborators of Mohammad Alzrigat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Alzrigat. Mohammad Alzrigat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	The inhibition of TXNRD1 by methylglyoxal impairs the intracellular control of Mycobacterium tuberculosis 2025 ·Redox Biology ·(unknown), Ruining Liu, (unknown), Radosveta Gencheva, Zhen Gong, (unknown), Mohammad Alzrigat, Lucia Coppo, Elias S.J. Arnér, Martı́n E. Rottenberg	0
2	Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC 2025 ·Molecular Pharmaceutics ·Carmine Pasquale Cerrato, (unknown), (unknown), Judit Liaño-Pons, (unknown), (unknown), Mohammad Alzrigat, Bořivoj Vojtěšek, David P. Lane, Marie Arsenian‐Henriksson, Ali Miserez, Michael Landreh	3
3	EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma 2024 ·Cell Death and Disease ·(unknown), Judit Liaño-Pons, Jiansheng Wang, Mohammad Alzrigat, Ye Yuan, María Victoria Ruiz-Pérez, (unknown), Elena Kashuba, Felix Haglund, Bertha Brodin, Marie Arsenian‐Henriksson	1
4	Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development 2023 ·Cancers ·Ye Yuan, Mohammad Alzrigat, (unknown), Xueyao Wang, Tomas Sjöberg Bexelius, John Inge Johnsen, Marie Arsenian‐Henriksson, Judit Liaño-Pons, Oscar C. Bedoya-Reina	4
5	MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma 2023 ·International Journal of Molecular Sciences ·Prasoon Agarwal, (unknown), (unknown), (unknown), Lars‐Gunnar Larsson, Mohammad Alzrigat	5
6	HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infection 2022 ·Nature Communications ·Ruining Liu, (unknown), Wenjun Mou, (unknown), Juan Yuan, Johan Holmberg, Benedict J. Chambers, (unknown), (unknown), Mohammad Alzrigat, Susanne Schlisio, Berit Carow, (unknown), Martı́n E. Rottenberg	15
7	Methods to Study Myc-Regulated Cellular Senescence: An Update 2021 ·Methods in molecular biology ·Fan Zhang, (unknown), Mohammad Alzrigat, Lars‐Gunnar Larsson	5
8	Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence 2020 ·Cell Cycle ·(unknown), Matteo Bocci, (unknown), Vedrana Tabor, Per Hydbring, Alf Grandien, Mohammad Alzrigat, Lars‐Gunnar Larsson	9
9	Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity 2018 ·Epigenomes ·Mohammad Alzrigat, Helena Jernberg‐Wiklund, Jonathan D. Licht	18
10	Epigenetics in multiple myeloma: From mechanisms to therapy 2017 ·Seminars in Cancer Biology ·Mohammad Alzrigat, (unknown), Helena Jernberg‐Wiklund	66
11	The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma 2017 ·PubMed ·Mohammad Alzrigat, Helena Jernberg‐Wiklund	19
12	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains 2017 ·Oncotarget ·Mohammad Alzrigat, (unknown), Muntasir Mamun Majumder, Anqi Ma, Jian Jin, Anders Österborg, Hareth Nahi, Kenneth Nilsson, Caroline A. Heckman, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg‐Wiklund	17
13	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions 2016 ·Oncotarget ·Mohammad Alzrigat, (unknown), Prasoon Agarwal, Hadil Zureigat, Anders Österborg, Hareth Nahi, Anqi Ma, Jian Jin, Kenneth Nilsson, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg‐Wiklund	46
14	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target 2016 ·Oncotarget ·Prasoon Agarwal, Mohammad Alzrigat, (unknown), Stefan Enroth, Umashankar Singh, Johanna Ungerstedt, Anders Österborg, Peter J. Brown, Anqi Ma, Jian Jin, Kenneth Nilsson, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg‐Wiklund	60
15	PML promotes MHC class II gene expression by stabilizing the class II transactivator 2012 ·The Journal of Cell Biology ·(unknown), Mohammad Alzrigat, (unknown), Nina Reuter, Anna von Mikecz, Viktor Steimle, Eberhard Schmitt, Oliver H. Krämer, Thomas Stamminger, Peter Hemmerich	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact